With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.112881-51-3,4′-(4-Pyridyl)-2,2′:6′,2”-terpyridine,as a common compound, the synthetic route is as follows.
The ligand Ptpy (pyridine terpyridine) was synthesised according to known procedures which involve the Kronke pyridine synthesis. A warm methanolic solution of Ptpy (0.310 g, 1 mM) was added to a MeOH solution of CuCl2¡¤2H2O (0.171 g, 1 mM) and kept for stirring for 3 h. A green precipitate was obtained in quantitative yield. After filtration the green precipitate was dissolved in methanol: acetonitrile (1:1) solution and heated to boil and kept aside for crystallization. Needle shaped crystals suitable for X-ray diffraction was obtained. Yield 86%. Elemental analysis data for C20H17Cl3CuN4O[Cu(Ptpy)(Cl)2]¡¤H2O¡¤Cl, calcd (%): C 48.11, H 3.43, N 11.22; found (%) C 47.93, H 3.32, N 11.16. ESI-MS m/z, found: 408.13(100%); calcd: [Cu63(Ptpy)(Cl)+] 408.76., 112881-51-3
112881-51-3 4′-(4-Pyridyl)-2,2′:6′,2”-terpyridine 11438308, acatalyst-ligand compound, is more and more widely used in various fields.
Reference£º
Article; Manikandamathavan, Verasuntharam M.; Rajapandian, Varatharaj; Freddy, Allen J.; Weyhermueller, Thomas; Subramanian, Venkatesan; Nair, Balachandran Unni; European Journal of Medicinal Chemistry; vol. 57; (2012); p. 449 – 458;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI